Ironwood gets U.S. rights to AZ's Zurampic

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) exclusive, U.S. rights to Zurampic lesinurad, which FDA approved in December in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout (see BioCentury Extra, Dec. 22, 2015).

Ironwood said it plans to launch Zurampic next half. The selective solute carrier family 22 organic anion urate transporter member 12 ( SLC22A12; URAT1) inhibitor has a boxed warning noting risk of renal failure. ...